Can patients with hepatitis B safely use tenofovir alafenamide tablets (Vemlidy)?

Tenofovir alafenamide tablets (Vemlidy/Vemlidy), as an HBV nucleoside analog reverse transcriptase inhibitor, has been approved in many countries for the treatment of chronic hepatitis B , including adults with compensated liver disease and children over 12 years old. Its mechanism of action is to inhibit viral replication and reduce serum HBV DNA levels, thereby reducing liver inflammation and reducing the risk of fibrosis and cirrhosis.

From the clinical safety point of view, tenofovir alafenamide fumarate tablets are well tolerated. Compared with early antiviral drugs, it has a lower impact on kidney function and bone density, making it suitable for long-term maintenance treatment. Common adverse reactions include mild headache, nausea, and mild gastrointestinal discomfort, which are tolerated by most patients and do not require discontinuation of treatment. For patients with renal insufficiency or concurrent use of nephrotoxic drugs, doctors will adjust the dose while monitoring renal function indicators to ensure safety.

In terms of liver function monitoring, the use of tenofovir alafenamide fumarate tablets usually requires regular detection of serum HBV DNA, liver function and other biochemical indicators to evaluate the treatment effect and early detection of possible abnormalities. For patients with compensated liver disease, long-term regular use of tenofovir alafenamide fumarate tablets is not only safe, but can also effectively inhibit the virus, reduce the burden of liver inflammation, and reduce the risk of cirrhosis and liver cancer.

In addition, tenofovir alafenamide fumarate tablets can be used in children and adolescent patients, but the dose needs to be adjusted according to age and weight. Its safety and tolerability have been shown to be stable in clinical trials. For hepatitis B patients, long-term standardized medication combined with regular follow-up can achieve safe and efficient antiviral control.

In summary, it is safe and feasible for patients with hepatitis B to use tenofovir alafenamide tablets under the guidance of a doctor. Through standardized medication, regular monitoring, and timely management of adverse reactions, patients can achieve long-term viral suppression, reduce the risk of liver damage, and significantly improve disease prognosis.

Reference materials:https://www.vemlidyhcp.com/